SANDOZ VIETNAM COMPANY LIMITED | EuroCham
Change your cover photo
Upload
SANDOZ VIETNAM COMPANY LIMITED
Change your cover photo
This user account status is Approved

This user has not added any information to their profile yet.

Company Profile

Our purpose at Sandoz is clear: pioneering access for patients.

We achieve this with our broad global portfolio of about 1,300 quality generic and biosimilar medicines. In 2024 alone, we provided over 900 million patient treatments, generating more than USD 19 billion in direct savings for US and
European healthcare systems. This significantly improves healthcare by freeing up resources, leading to an estimated total social impact of around USD 400 billion per year worldwide.
Our products are broadly divided into biosimilars and generics. We focus on driving access to make a real difference for patients, and we're already doing it in a very tangible way.
How? We specialize in developing more affordable versions of high-quality medicines once their key patents have expired. For us, pioneering access means constantly innovating: finding new ways to develop products aligned with patient needs, producing cutting-edge medicines at prices people can afford, and ensuring these medicines reach the patients who need them most.
As the leading supplier of these medicines – which account for around 80% of medicines worldwide – we make high-quality healthcare more affordable. Looking ahead, we expect to make an even greater difference for those who need affordable, sustainable, and high-quality healthcare.

PHARMACEUTICALS, BIOTECHNOLOGY, LIFE SCIENCES
101-500

Company Information

SANDOZ VIETNAM COMPANY LIMITED

Company Profile

Company Description

Our purpose at Sandoz is clear: pioneering access for patients.

We achieve this with our broad global portfolio of about 1,300 quality generic and biosimilar medicines. In 2024 alone, we provided over 900 million patient treatments, generating more than USD 19 billion in direct savings for US and
European healthcare systems. This significantly improves healthcare by freeing up resources, leading to an estimated total social impact of around USD 400 billion per year worldwide.
Our products are broadly divided into biosimilars and generics. We focus on driving access to make a real difference for patients, and we’re already doing it in a very tangible way.
How? We specialize in developing more affordable versions of high-quality medicines once their key patents have expired. For us, pioneering access means constantly innovating: finding new ways to develop products aligned with patient needs, producing cutting-edge medicines at prices people can afford, and ensuring these medicines reach the patients who need them most.
As the leading supplier of these medicines – which account for around 80% of medicines worldwide – we make high-quality healthcare more affordable. Looking ahead, we expect to make an even greater difference for those who need affordable, sustainable, and high-quality healthcare.

Business Category

PHARMACEUTICALS, BIOTECHNOLOGY, LIFE SCIENCES

Number of Employees in Vietnam

101-500
Company Information

Company Name

SANDOZ VIETNAM COMPANY LIMITED

Address

Unit 1601 – Floor 16, Centec Tower, 72-74 Nguyen Thi Minh Khai St., Xuan Hoa Ward, Ho Chi Minh City
Representative Profiles

Log in as a member to access the details. Not a member? Contact our Membership team at (84-28) 3827 2715 ext 105 or membership@eurochamvn.org

Change your cover photo
Upload
SANDOZ VIETNAM COMPANY LIMITED
Change your cover photo
This user account status is Approved

This user has not added any information to their profile yet.

Company Profile

Our purpose at Sandoz is clear: pioneering access for patients.

We achieve this with our broad global portfolio of about 1,300 quality generic and biosimilar medicines. In 2024 alone, we provided over 900 million patient treatments, generating more than USD 19 billion in direct savings for US and
European healthcare systems. This significantly improves healthcare by freeing up resources, leading to an estimated total social impact of around USD 400 billion per year worldwide.
Our products are broadly divided into biosimilars and generics. We focus on driving access to make a real difference for patients, and we're already doing it in a very tangible way.
How? We specialize in developing more affordable versions of high-quality medicines once their key patents have expired. For us, pioneering access means constantly innovating: finding new ways to develop products aligned with patient needs, producing cutting-edge medicines at prices people can afford, and ensuring these medicines reach the patients who need them most.
As the leading supplier of these medicines – which account for around 80% of medicines worldwide – we make high-quality healthcare more affordable. Looking ahead, we expect to make an even greater difference for those who need affordable, sustainable, and high-quality healthcare.

PHARMACEUTICALS, BIOTECHNOLOGY, LIFE SCIENCES
101-500

Company Information

Marieke Van Der PIJL

VICE CHAIR

Corem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis.